| Status: Medicine does not meet criteria for AWMSG assessment | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1026: Tirzepatide for managing overweight and obesity |
|
Medicine details |
|
| Medicine name | tirzepatide (Mountjaro®) |
| Formulation | solution for injection |
| Reference number | 5249 |
| Indication | Treatment for obesity, overweight |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Nutrition & blood |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 21/03/2023 |
| NICE guidance | |